Related Experiment Video
Updated: May 23, 2026

Ex Vivo Release of Calcitonin Gene-Related Peptide from the Trigeminovascular System in Rodents
Published on: May 16, 2022
Pharmacological mechanisms underlying neurovascular alterations related to resistant and refractory migraine: CGRP
Damiana Scuteri1, Michalis Kodounis2,3, Masahito Katsuki4,5
1Department of Health Sciences, University "Magna Graecia" of Catanzaro, Catanzaro, Italy.
Background:
Migraine is the fourth leading cause of disability worldwide. It impairs patients' physical, emotional and social functioning, as well as their productivity. This is also due to poor pharmacological control of attacks in difficult-to-treat patients. Despite several therapeutic strategies available, including the game-changing calcitonin gene-related peptide (CGRP)-targeted small-molecule and biotechnological drugs, 40% of patients remain resistant or even refractory. The aim of this review is to highlight the neurovascular mechanisms underlying poor response or nonresponse to antimigraine drugs, with particular focus on the phenomena related to the CGRP pathway.
Methods:
Eligibility criteria, search strategy and information sources were established a priori: PubMed, Scopus, Cochrane Library, Web of Science and ScienceDirect were searched for studies published from database inception to the date of the last search on July 05th, 2025.
Results:
Non-response to antimigraine treatment is closely linked to clinical and neurobiological factors that increase the overall disease burden. Underlying these challenges are mechanisms involving genetic and epigenetic modifications that contribute to inter-individual variability in pharmacokinetics and pharmacodynamics. Additionally, CGRP as well as other neuropeptides, implicated in the neurovascular basis of migraine, may play a significant role. Targeting these mechanisms may help overcome treatment resistance and refractoriness, as defined by the European Headache Federation. Combination therapies, including the latest available treatments, might represent a promising strategy. Thus, they deserve further investigation to confirm efficacy without worsening the safety profile.
Conclusions:
A deeper understanding of the neurovascular pharmacology and pathophysiology of migraine is essential to pave the way for more personalized and effective treatments. tudies are needed to clarify the neuropharmacological, genetic, and epigenetic mechanisms that underlie resistance and refractoriness to pharmacological therapies, affecting the CGRP pathway both directly and indirectly.
Clinical Trial Number:
Not applicable.
Related Concept Videos
Neurochemical Transmission: Sites of Drug Action
Drugs Affecting Neurotransmitter Release or Uptake
Ligand-Gated Ion Channel Receptor: Gating Mechanism
Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists
Analgesia and Pain Management
Adrenergic Agonists: Indirect-Acting Agents
One mechanism involves depleting stored catecholamines by displacing them from synaptic vesicles. These agents, known as "displacers," are transported into vesicles at the expense of noradrenaline. Examples include amphetamine and tyramine, which lack a catechol moiety, resulting in prolonged action, improved oral bioavailability, and...

